Revenue
No reported data
Edgewise Therapeutics, Inc. (EWTX)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Research & development | $151.4M | $127.0M | $90.9M | $54.0M | $32.2M | $15.0M |
| Operating expenses | $191.4M | $158.8M | $114.4M | $71.7M | $43.2M | $17.2M |
| Operating income | −$191.4M | −$158.8M | −$114.4M | −$71.7M | −$43.2M | −$17.2M |
| Net income | −$167.8M | −$133.8M | −$100.2M | −$67.6M | −$42.8M | −$17.1M |
| Basic EPSper diluted share | -$1.63 | -$1.45 | -$1.57 | -$1.26 | -$1.14 | -$23.17 |
| Diluted EPSper diluted share | -$1.63 | -$1.45 | -$1.57 | -$1.26 | -$1.14 | -$23.17 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 5, 2026Form 4 | Donovan Joanne M.CMO | SellCommon Stock | 50.0K | $38.57 | $1.93M | 4.4K |
| May 4, 2026Form 4 | Donovan Joanne M.CMO | SellCommon Stock | 5.2K | $31.29 | $163.6K | 4.4K |
| Apr 1, 2026Form 4 · 10b5-1 | Donovan Joanne M.CMO | SellCommon Stock | 28.7K | $32.31 | $926.1K | 9.6K |
| Mar 31, 2026Form 4 · 10b5-1 | Donovan Joanne M.CMO | SellCommon Stock | 21.3K | $32.12 | $685.4K | 9.6K |
| Mar 27, 2026Form 4 · 10b5-1 | Donovan Joanne M.CMO | SellCommon Stock | 6.7K | $30.98 | $208.7K | 9.6K |